Profound Medical (TSE:PRN) has released an update.
Profound Medical has appointed Tom Tamberrino as Chief Commercial Officer to drive the widespread adoption of its TULSA technology, a promising treatment for prostate disease. This strategic move comes ahead of anticipated changes in reimbursement codes that could significantly boost the company’s market position.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
